RepliCel Life Sciences, Inc.の配当落ち日はN/Aです。
配当落ち日は、売却後の配当金の支払いが売り手の代わりに新しい所有者に帰属する前の期限です。
The ex-dividend date or reinvestment date is an investment term involving the timing of payment of dividends on stocks of corporations, income trusts, and other financial holdings. If a sale is before this date, the dividend belongs to the new owner; if on or after the date, the seller is entitled to the dividend. If a stock is purchased on its ex-dividend date or after, the buyer will not receive the next dividend payment. Instead, the seller gets the dividend. If a stock is purchased before the ex-dividend date, the buyer gets the dividend.
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.